Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.

• Status: Completed
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Oxidative stress has been reported to play a role in melasma pathophysiology. The objective of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to sunscreen to decrease melasma severity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nice
• Treatments: Superoxide Dismutase

Criteria

Inclusion Criteria:

• Clinically diagnosed melasma in adult patient

• signed inform consent

Exclusion Criteria:

• Pregnant women

• Other pigmentary disorder of the afce

• Use of depigmentant agent in the month before the inclusion

• Use of topical steroid, tretinoin, hydroquinone in the month before the inclusion

• Coeliac disease or allergy to gluten